Search results for: psoriatic arthritis

An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

Residents from the RheumMadness Leadership Team: Michael Macklin, MD, PharmD; Ben Kellogg, MD; Lauren He, MD; & David Leverenz, MD | February 8, 2022

According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

Order in the Inflammatory Mess: RheumMadness 2022 Cytokine Networks Scouting Report

Rheumatology Leadership Team: David Leverenz, MD; Akrithi Udupa, MD; Guy Katz, MD; Lauren He, MD; Ben Kellog, MD; Michael Macklin, MD; Courtney Bair; Matthew Sparks, MD; & Lisa Criscione-Schreiber, MD, MEd | February 8, 2022

Research has identified and described a pro-inflammatory cytokine network shared by four rheumatic conditions that may be particularly active in patients with severe disease.

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

Michele B. Kaufman, PharmD, BCGP | February 2, 2022

The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.

Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors

Arthritis & Rheumatology | February 2, 2022

In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.

The 2021 ACR Awards of Distinction & Distinguished Fellows

Patrice Fusillo | December 16, 2021

During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

Thomas R. Collins | December 9, 2021

Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH | December 7, 2021

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR | November 23, 2021

The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

Michele B. Kaufman, PharmD, BCGP | November 17, 2021

Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.

The 2021 ARP President’s Awards & Merit Awards

Patrice Fusillo | November 14, 2021

During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…